PDT for Lung Cancer2016 but very interesting paper from Roswell Park Institute.
TLT will probably go alone all the way to end of Ph. 2b on this one too, just like with the NMIBC indication, as the market valaution for this one is a monster one, as per these numbers below:
Jan. 21, 2017
Lung cancer: Merck to pay Bristol-Myers 625M$ + royalties
Want to know the money involved when winning a blockbuster race?
Before the first deception of August 2016, Bristol-Myers-Squibb (BMS) had a market cap of 125,849,064,856$.
After yesterday's news where it will not seek for a FDA Fasttrack approval, BMS had a market cap of 82,274,650,242$.
Total lost of value of 43.5G$ in 6 months from BMS because its drug is seen less convincing than Merck's one.
Merck, during the same timeframe, gained +12,301,222,809$ in market valuation (went from 160,102,586,129$ to 172,403,808,938$), despite this patent litigation resolution news yesterday:
Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA® (pembrolizumab).
Under the settlement and license agreement, Merck will make a one-time payment of $625 million to Bristol-Myers Squibb and provide royalties on the worldwide sales of KEYTRUDA for a non-exclusive license to market KEYTRUDA in any market in which it is approved. For global net sales of KEYTRUDA, the company will pay Bristol-Myers Squibb royalties as follows:
- 6.5% of net sales occurring from Jan. 1, 2017 through and including Dec. 31, 2023; and
- 2.5% of net sales occurring Jan. 1, 2024 through and including Dec. 31, 2026.
_____________
Jan. 6, 2017: These are the market shares lost today, on that news:
Bristol-Myers shares drop after company says it will not seek fast-track drug approval
Still expected to receive approval in the second half of 2018.
In one day trading, BMS lost 10,461,899,461$ in market valuation because of the failing of its 150,000$/patient blockbuster immuno-therapy drug Opdivo in the lung cancer (non-small cell lung cancer).
Before this news, BMS had a market cap of 92,736,549703$.
With this bad news, it now has a market cap of 82,274,650,242$.
It goes to tell you how this lung indication market (#1 killer) is important.
Bristol-Myers Squibb Company
Exchange: New York Stock Exchange | Jan 20, 2017, 4:15 PM EST
Shares Out.: 1,671,229,946
Market Cap: 82,274,650,242$
Now, lets take a look at its direct competitor:
Merck & Company Inc. (new)
Exchange: New York Stock Exchange | Jan 20, 2017, 4:20 PM EST
$ 62.53
Shares Out.: 2,757,137,517
Market Cap: 172,403,808,938$
Its competitor Merck, gained +3.65% because of one less competitor in this lung cancer market. This translates into an additional +6,065,702,537$ market valuation for Merck.
_____________
August 6, 2016 11:44 AM
WSJ ... Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study
Check this graph. in this morning's WSJ.com:
In one day trading, BMS lost 20,117,136,781$ in market valuation because of the failing of its 150,000$/patient blockbuster immuno-therapy drug Opdivo in the lung cancer (non-small cell lung cancer).
Before this news, BMS had a market cap of 125,849,064,856$.
With this bad news, it now has a market cap of 105,731,928,095$.
It goes to tell you how this lung indication market (#1 killer) is important.
$ 63.28 
Shares Out.: 1,670,858,535
Market Cap: 105,731,928,095
Now, lets take a look at its direct competitor:
$ 63.86
Shares Out.: 2,768,025,348
Market Cap: 176,766,098,723
Its competitor Merck, gained +10% because of one less competitor in this lung cancer market. This translates into an additional +16,663,512,594$ market valuation for Merck.
_________________
And Merck's Keytruda is being used in conjunction with chemo and is not even destroying tumour. And they have 314M$ sales/quarter!